No One Wants Rockwell’s Triferic, Apparently
Insights - Rockwell Medical (RMTI) reported sales of Triferic in the first quarter of … none. Rockwell sold $200K worth of Triferic in the fourth quarter of … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Ariad’s Strategic Review, Step Two
Research - Ariad Pharmaceuticals (ARIA) took the second step in its ongoing strategic restructuring on Monday, announcing the sale of its European unit and rights to Iclusig … Continue Reading
Read now
Simply Sit on That Sarepta Trade, and More Updates
Research - The NASDAQ Biotech Index Fund (IBB) failed to break out from $285 last week (discussed two weeks ago in our webinar) and subsequently lost key … Continue Reading
Premium
Which Will Trump: Healthcare M&A, or Earnings?
Insights - With three pieces of M&A news on Thursday morning, and a mixed bag of earnings from large bio/pharma companies so far this week, investors will see what they want … Continue Reading
Read now
Does The Latest For Linzess Read Through to Synergy?
Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
Premium
Our First ‘Healthcare Huddle’ Webinar
Research - At PropThink, we experimented with some educational/informational webinars late in 2015 and early in 2016. The reception from our members was great.
Read now
Bluebird Bio’s CALD Data, And Other Updates
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
Premium